ABBOTT's TIAGABINE REDUCES COMPLEX PARTIAL SEIZURES BY 29%

ABBOTT's TIAGABINE REDUCES COMPLEX PARTIAL SEIZURES BY 29% "in a very refractory patient population," according to Phase III study results presented at the Dec. 5 American Epilepsy Society meeting in New Orleans. "Control of complex partial seizures was significantly better among patients receiving 32 mg or 56 mg tiagabine HCl per day compared to placebo," Abbott said. The study "showed a significant correlation between increasing doses of tiagabine HCl and response." In addition, "statistical significance was also proven in adjunctive tiagabine therapy against secondarily generalized tonic-clonic seizures."